All In Biotech

Drug Trial Radar · NCT06713590

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

A Phase 1, Open-Label, Randomized Study of Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jan 14, 2025

Primary completion

Jun 6, 2025

Study completion Jun 10, 2025

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Dec 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.

Conditions

  • Healthy Participants

Interventions

  • AxatilimabDrug

    Axatilimab will be administered at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics Parameter: Cmax of axatilimabTime frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60
  2. Pharmacokinetics Parameter: AUC(0-t) of axatilimabTime frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60
  3. Pharmacokinetics Parameter: AUC 0-∞ of axatilimabTime frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60
  4. Number of participants with Treatment Emergent Advers Events (TEAE's)Time frame: Up to 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.